Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q4 FY2020 Earnings Presentation
21 slides from Lincoln Pharmaceuticals's earnings presentation, 2020
Slide 1: Q4 and Full Year FY2020 Earnings Presentation
Providing Affordable and Innovative medicines for healthier lives Q4 and Full Year FY2020 Earnings Presentation 1 www.lincolnpharma.com
Slide 2: Highlights
Highlights FY2020 vs. FY2019 Management Perspective o Total Income of Rs. 3,975 million, up 6.9% “Lincoln Pharma’s performance during the year was encouraging despite the prevailing challenging economic and business scenario globally. Export business o EBITDA of Rs. 766 million, up 5.1% has seen goo
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q4 y-o-y Q3 q-o-q Full Year y-o-y Particulars FY2020 FY2019 Growth (%) FY2020 Growth (%) FY2020 FY2019 Growth (%) Net Revenue 827 784 5.4% 1,016 (18.6)% 3,975 3,718 6.9% EBITDA 128 104 23.6% 162 (21.1)% 766 728 5.1% Margin (%) 15.5% 13.2% 16.0%
Slide 4: Performance Overview: Revenue Breakup
Performance Overview Revenue Breakup 4% 2% 3% 2% General Anti Infectives 9% 24% 24.9% 24.1% 22.1% 25.1% Respiratory Systems Therapeutic Area 14% Alimentary Tract and Metabolism 0.3% Genito Urinary System and Sex Hormones FY20 3.4%13% FY19 15% Musculo-Skeletal System 0.1% 3.4% 8.5% 0.5% 14% Parasitol
Slide 5: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) 15.4% (3.9)% 7.6% 19.7% 5.4% 784.5 981.1 1,152.1 1,015.6 826.5 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 EBITDA (Rs. million) and Margin (%) 23.6% 20.7% 16.0% 15.5% 13.2% 103.6 203.4 272.0 162.3 128.0 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4
Slide 6: Performance Trend
Performance Trend Total Debt / LTM EBITDA Total Debt / Net Worth 0.62x 0.54x 0.15x 0.12x 0.25x 0.06x 0.06x 0.06x 0.02x 0.01x Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 ROCE1 RONW2 24.4% 18.1% 21.1% 21.8% 16.0% 16.5% 17.0% 16.4% 18.8% 19.3% Q4 FY19 Q1 FY20 Q2 FY20
Slide 7: Leverage Profile
Leverage Profile (Rs. million) Mar-20 Mar-19 Credit Rating Long Term Debt 8 17 o CRISIL Short Term Debt 38 30 ▪ Long term rating: A-/Stable Total Debt 47 47 ▪ Short term rating: A2+ o ICRA Less: Cash & Cash Equivalents 122 55 ▪ Long term rating: A-/Stable to A-/Positive Net Debt / (Net Cash) (75) (8
Slide 8: Recent Developments
Recent Developments 1 Secured a patent for Diclofenac Rectal Spray • Recently the company has been awarded with a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray) • The company has necessary approvals from Drug Controller General of India (DCGI) and planning to la
Slide 9: Recent Developments
Recent Developments 4 Amalgamation between Lincoln Parenteral Limited and Lincoln Pharmaceuticals Limited • Recently board of directors of the company approved the scheme of amalgamation between Lincoln Parenteral Limited ("Transferor Company") and Lincoln Pharmaceuticals Limited ("Transferee Compan
Slide 10: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 4.0% 3.2% 2.8% 2.4% 2.0% 2.7% 148.1 Senior Scientist 15 117.3 106.6 Junior Scientist 18 1.6% 88.5 Analysts 18 79.5 72.6 Regulatory Personnel 12 Administrative Personnel 9 34.3 Others 6 Total 78 FY14 FY15 FY16 FY17
Slide 11: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 7 Patents granted 1,700 Registered products 60+ 26 25 Patents applications 700 in pipeline Countries States across India 600+ 72nd 15+ Formulations developed Rank in AIOCD Therapeutic areas 650
Slide 12: Key Milestones
Key Milestones Received Patent for Diclofenac Rectal Received WHO – Becomes Public Covered 80% Installed Windmill Developed & Launch 3 products which are Spray GMP for plant / Limited Company of all India 600 KVA launched 2 more first time in India. Entered in Targeting many new countries in West pr
Slide 13: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 26 States across India Europe: France South & Central Asia : Afghanistan, Armenia, America : Bolivia, Africa: Angola, Benin, Botswana, Azerbaijan, Bhutan, Cambodia, Chile, Costa Rica, Bu
Slide 14: Best in Class Facilities
Best in Class Facilities Certifications: WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Cap
Slide 15: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-malarial Anti-viral/ Anti- Otology / Anti-o
Slide 16: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 α-β Arteether Injection Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride 150mg/ 2 ml Effective Anti- Malarial Kingping Heparin
Slide 17: Key Developments
Key Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better patient com
Slide 18: Key Developments
Key Developments o Domi Up Spray • Meter dose pump • Each squirt (spray) accurately delivers 2 mg Ondansetron Hydrochloride • Faster onset of action • Prompt relief from nausea & vomiting • Convenient for patient over Injectable • Better patients compliance o Namcold DX • First time in India: ‘Exten
Slide 19: Key Developments
Key Developments o USP INFITY - YS • Most stable derivative of Vitamin C (at 450C) • Easy to penetrate skin • Molecular weight of Hyaluronic acid in INFITY – YS is equivalent to 1000 KDal o USP INFITY - HS • Revitalized the DPC • Covering all aspects of Baldness in one solution • Powered with the Ha
Slide 20: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 21: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060. Gujarat, INDIA. Phone :+91-79-4107 8000 • Fax:+91-79-4107 8062 E-mail: info@lincolnpharma.com www.lincolnpharma.com CIN: L24230GJ1995PLC024288 KP Sompura Finance Head, Lincoln Pharmaceuticals sompurakp@
Lincoln Pharmaceuticals — Q4 FY2020 Earnings Presentation on 6ix